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Abstract
Objective To present the evidence of the effectiveness and safety of Chinese herbal medicine (CHM)
used with or without conventional western therapy on COVID-19.
Methods Clinical studies on effectiveness and safety of CHM for COVID-19 were included. We
summarized general characteristics of included studies, evaluated methodological quality of
randomized controlled trials (RCTs) using the Cochrane risk of bias tool, analyzed the use of CHM,
used Revman 5.4 software to present the risk ratio (RR) or mean difference (MD) with their 95%
confidence interval (CI) to estimate the effectiveness and safety of CHM.
Results A total of 58 clinical studies were identified including RCTs (17.24%, 10), non-randomized
controlled trials (1.72%, 1), retrospective studies with a control group (18.97%, 11), case-series
(20.69%, 12) and case-reports (41.38%, 24). No high methodological quality RCTs were identified.
The most frequently tested Chinese patent medicine, Chinese herbal medicine injection or prescribed
herbal decoction were: Lianhua Qingwen granule/capsule, Xuebijing injection and Maxing Shigan
Tang. In terms of aggravation rate, pooled analyses showed that there had statistical differences
between the intervention group and the comparator group (RR 0.46, 95% CI 0.30 to 0.68, 7 RCTs;
RR 0.37, 95% CI 0.22 to 0.64, 4 retrospective studies with control group), that is, CHM plus
conventional western therapy appeared better than conventional western therapy in reducing
aggravation rate. In addition, compared with conventional western therapy, CHM plus conventional
western therapy had potential advantages in increasing the resolution rate and shortening the duration
of fever, cough and fatigue, improving the negative conversion rate of nucleic acid test, and
increasing the number of patients with inflammatory disappearance or shortening the time from
receiving treatment to beginning of inflammation disappearance. For adverse events, pooled data
showed that there was no statistical difference between the CHM and the control groups.
Conclusion Current low certainty evidence suggests that there maybe a tendency that CHM plus
conventional western therapy is superior to conventional western therapy alone. The use of CHM did
not increase the risk of adverse events.
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1 Introduction
Novel coronavirus pneumonia (NCP), officially named as Coronavirus Disease 2019 (COVID-19)
by the World Health Organization (WHO)1, is an acute respiratory infectious disease caused by
severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) which has affected the general
population. The main symptoms of COVID-19 are fever, dry cough and fatigue, and may be
accompanied by nasal congestion, runny nose, sore throat, diarrhea, or loss of taste and smell
anosmia.2 In traditional Chinese medicine, COVID-19 is classified within the pestilential (Yibing, 疫
病) category. The National Health Commission of the People’s Republic of China has incorporated
COVID-19 into the category B infectious diseases as stipulated in the Law of the People’s Republic
of China on the Prevention and Control of Infectious Diseases, and carried out prevention and control
management following category A infectious diseases. On 11 March 2020, the director-general of
World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, declared that COVID-19 was
now characterized as a pandemic3, that is, COVID-19 had spread worldwide, and posed a great
challenge and threat to the existing public health resources.
At present, there is no specific and effective therapy for the treatment and prevention of this
disease.4,5 Traditional Chinese medicine (TCM) has accumulated thousands of years of experience on
the use of Chinese herbal medicine (CHM) to prevent and treat infectious diseases6. Its success was
initially substantiated by modern human clinical research on severe acute respiratory syndrome
(SARS) and H1N1 influenza epidemics, suggesting that using historical CHM experience may be a
worthwhile approach.7 As this current epidemic escalated into a pandemic, the National Health
Commission of the People’s Republic of China has released multiple editions of guidelines for the
diagnosis and treatment of COVID-19 (hereinafter referred to as GDT of COVID-19). In the third
edition8, CHM was recommended for the treatment of COVID-19, and all relevant medical
institutions were required to actively encourage of the use of CHM in the treatment of COVID-19.
The early application of CHM during the COVID-19 pandemic and appeared to have a potentially
beneficial effects. CHM has increasingly shown its potential in the treatment and prevention for
infectious diseases, and has received widespread attention.
To further probe the role of CHM used with or without conventional western therapy on the
treatment of COVID-19, an evidence-based approach was employed to systematically collate,
analyze and evaluate clinical studies on the effectiveness and safety of using CHM for COVID-19.
2 Materials and methods
2.1 Inclusion and exclusion criteria of studies
The following criteria were used to identify relevant studies.
Inclusion criteria were as follows: (1) Clinical studies which aimed to evaluate the effectiveness
and/or safety of CHM used with or without conventional western therapy in patients with COVID-19;
(2) There were no limits on the study design and could be randomized controlled trials (RCT), non-
randomized controlled trials (non-RCT), cohort studies, case series, case reports or other study
designs; (3) Participants were patients diagnosed with COVID-19. Disease severity could be mild,
common, severe or critical, as prescribed in the guideline for the diagnosis and treatment of COVID-
19 formulated by the National Health Commission of the People’s Republic of China. There was no
limitation on participants' age, gender and their ethnicity, or the setting of the studies; (4) The
interventions in the experimental group were CHM and included prescribed herbal decoctions, oral
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Chinese patent medicines (capsules, tablets or granules) or Chinese herbal medicine injection, or
CHM combined with comparators. For controlled clinical studies, comparators could be conventional
western therapy or placebo.
Exclusion criteria were: (1) The full text of the studies could not be obtained; (2) Any duplicated
articles; (3) Registered clinical studies but had not started or completed; (4) Clinical studies that had
been registered and completed but had not published research data, and the data which could not be
obtained by contacting the authors; (5) If the registered protocol and published articles were from the
same study, the protocol was excluded.
2.2 Retrieval platforms and search strategies of studies
Studies were retrieved through nine electronic databases including: China National Knowledge
Infrastructure (CNKI, as of April 30, 2020), Wanfang Database (from January 1 to April 30, 2020),
the China Science Technology Journal Database (VIP, from January 1 to April 30, 2020), SinoMed
(from January 1 to April 30, 2020), PubMed (from January 1 to April 30, 2020), Embase (from
January 1 to April 30, 2020), BioRxiv (as of April 30, 2020), MedRxiv (as of April 30, 2020), arXiv
(as of April 30, 2020) and clinical trial registration platforms (CTRPs) including ClinicalTrials.gov
(www.clinicaltrials.gov, as of April 30, 2020) and Chinese Clinical Trial Registry (ChiCTR,
www.chictr.org/cn, as of April 30, 2020).
For the databases/CTRPs with COVID-19 thematic platforms, including CNKI and
ClinicalTrials.gov, the search was performed directly in the COVID-19 thematic platform. For
Wanfang, VIP, SinoMed, PubMed and Embase, search terms were used. The search terms included
Xinxing Guanzhuang Bingdu Bing (新型冠状病毒病 ), Xinguan Feiyan (新冠肺炎 ), 2019
Guanzhuang Bingdu Bing (2019 冠状病毒病 ), coronavirus disease-19, COVID-19, 2019 novel
coronavirus, 2019-nCOV, NCP, Zhongyi (中医), Zhongyao (中药), Caoyao (草药), Tangji (汤剂),
Zhongchengyao (中成药), Zhusheji (注射剂), Zhongxiyi Jiehe (中西医结合), Chinese medicine,
traditional Chinese medicine, herbal medicine, decoction, patent medicine, injection, integrated
Chinese and western medicine. For ChiCTR, title search was carried out using Xinxing Guangzhuang
Bingdu (新型冠状病毒) and COVID-19 as search terms. For BioRxiv, MedRxiv and arXiv, title or
abstract search was carried out using COVID-19 as search terms. Appendix 1 shows the search
strategies for the nine electronic databases and CTRP.
Before submission, we updated the search and included the latest published studies that met the
inclusion criteria.
2.3 Study selection and data extraction
Published studies were screened according to the inclusion/exclusion criteria by titles, abstracts
and (or) full texts of the published articles. Registered studies were screened according to the
inclusion/exclusion criteria by reading the titles and details of registered protocols. SBL, YYZ, CS,
CHL, YQL, BYL and ZYT were responsible for the selection of articles.
Excel 2010 was used to provide the data sheets for extraction. Extracted items include first author's
name or registered protocol’s ID, study titles, the country in which the study was carried out, study
design, characteristics of participants (such as sample size, age, gender, severity of COVID-19, etc.),
details of interventions and outcomes, etc. For each included study, two authors independently
extracted and checked the data. The inconsistencies were resolved by the two authors through
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consultation. If any disagreements, a third author (JPL) was consulted. LSB, YYZ, YQL, CS, BYL,
ND, YJ, XWZ, CHL, YPZ and MX participated in data extraction in pair.
2.4 Outcomes
Primary outcomes included cure rate, mortality rate and aggravation rate.
Secondary outcomes included the disappearance rate or the duration of main symptoms (including
fever, cough and fatigue), negative conversion rate of nucleic acid test for SARS-Cov-2,
inflammatory disappearance on chest CT, length of hospitalization and adverse events.
2.5 Design of this review and data synthesis
This is an evidence review of clinical studies on the effectiveness and safety of CHM used with or
without conventional western therapy on COVID-19. Initially, we summarized the general
characteristics of the included studies and then the methodological quality of included RCTs was
assessed by SBL and YQL using the Cochrane risk of bias tool9. Subsequently, counts and
percentages were applied to analyze the use of CHM. Lastly, we evaluated the effectiveness and
safety of CHM used with or without conventional western therapy on COVID-19. For studies
without control group, such as case series and case reports, we only presented these findings
qualitatively as they were not sufficient to probe the therapeutic effect of CHM for COVID-19 due to
the absence of control and a high risk of bias in case selection. For studies with control group, we
used Cochrane Collaboration Review Manager 5.4 (Revman 5.4) software to conduct meta-analysis
of the data. We presented binary data as a risk ratio (RR) with its 95% confidence interval (CI), and
continuous data as a mean difference (MD) with its 95% CI. Considering potential sources of clinical
heterogeneity, the random-effect model (REM) was used for meta-analysis. We planned to conduct
the following subgroup analysis for the primary outcomes if data were available: (1) subgroup
analysis based on the severity of COVID-19, to detect whether the effectiveness of CHM is related to
the severity; (2) subgroup analysis based on the use of CHM with or without conventional western
therapy, to detect whether CHM alone or whether CHM plus conventional western therapy is more
beneficial for treatment of COVID-19.
3 Results
3.1 Search results
Fig.1 shows the flow diagram for the searching and screening of published articles. A total of 4763
published articles were retrieved from the above-mentioned nine open electronic databases, of which
102 articles were selected by reading full-texts and 54 were removed for various reasons. Finally,
4810-57 published articles (representing 48 completed studies) met the inclusion criteria. Before
submission, we updated the search and included 10 further completed studies58-67 that met the
inclusion criteria. Fig. 2 shows the flow diagram for searching and screening of registered clinical
studies. A total of 1669 registered protocols were retrieved from the above-mentioned two CTRPs
and 50 registered protocols (50 registered clinical studies) meeting the inclusion criteria. However,
all the 50 registered studies were excluded due to their status as ‘not yet started’ or ‘in progress’.
Therefore, 58 published articles10-67 (representing 58 completed studies) were included in our
review.
Insert Fig.1
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Insert Fig.2
3.2 The characteristics of included 58 clinical studies
All the 58 clinical studies were conducted in China. Of these, 52 were published in Chinese10-
15,17,18,20-53,57-66 and 6 were in English16,19,54-56,67. Among the included studies, 10 (17.24%) were
RCTs10-16, 58-59, 67, one (1.72%) was non-RCT17, 11 (18.97%) were retrospective studies with control
group18-27,60, 12 (20.69%) were case-series28-37,61,62, 24 (41.38%) were case-reports38-57,63-66.
Of 2773 COVID-19 patients involved in the included studies, 1921 (69.28%) received CHM. The
level of severity of COVID-19 involved non-serious (including mild and common) and serious
(including severe and critical). Of the included 58 studies, 29 (50.00%) studies10-14,17,18,20,23,25,27,28,34-
38,41,49-51,57-61,63,66,67 included only non-serious patients, 12 (20.69%) studies16,22,30,31,44,45,47,48,53,55,56,65
included only serious patients, 11 (18.97%)15,19,24,26,29,32,39,42,46,54,62 included both non-serious and
serious patients, and the remaining 6 (10.34%) studies21,33,40,43,52,64 did not report the level of severity
of COVID-19.
Of the included 58 studies, 8 (13.79%)29,40,42,51,56,57,63,64 involved the alone use of CHM, and 51
(87.93%)10-28,30-39,41,43-50,52-56,58-62,65,66 involved CHM used in combination with conventional western
therapy (such as abidor, ganciclovir, lopinavir, oxygen inhalation, nutritional support, etc.). The
course of treatment varied from 4 to 15 days.
Table 1 shows the characteristics of the 58 included studies.
Insert Table 1
3.3 Methodological quality of RCTs
In terms of the random sequence generation methods of the included 10 RCTs10-16,58,59,67, 6 RCTs10-
13,58,67 used random number tables, 2 trials15,16 used a simple random allocation method and the
remaining 2 RCTs14,59 only mentioned random without describing the detailed randomization method.
Two RCTs16,67 performed allocation concealment. Therefore, the risk of selection (allocation) bias
was unclear for the majority of the included RCTs due to lack of information on allocation
concealment. Due to no trials used blinding to participants and personnel, the performance bias of all
the included trials was judged as high-risk. Two RCTs16,67 performed outcome assessor blinding and
the remaining 8 RCTs10-15,58,59 did not report relevant information, thus the detection bias for majority
of the included RCTs was judged as unclear-risk. In terms of attrition bias, 8 RCTs11-13,15,16,58,59,67
were assessed as low-risk of bias due to complete outcome data or incomplete outcome data being
adequately addressed, 2 RCTs10,14 were assessed as high-risk due to incomplete outcome data that
were not adequately addressed. Two RCTs16,67 registered the study protocol and reported the
registration information. By comparison, we found that there was no selective reporting of outcomes
in these two RCTs, so their reporting bias was evaluated as low-risk. Since the protocols or
registration information of the other 8 included RCTs10-15,58,59 were not available, the selective
reporting of outcomes in these RCTs could not be judged and the reporting bias of these was assessed
unclear-risk. All 10 RCTs reported the comparability of baseline data, so they were assessed as
having a low-risk of other bias.
Fig.3 demonstrates the risk of bias of included 10 RCTs.
Insert Fig.3
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3.4 Analysis of the use of CHM
For the type of CHM, 24 (41.38%) studies10-14,17-19,23-27,31,34,36,38,39,51,53,54,56,57,60 tested oral Chinese
patent medicine, 40 (68.97%) studies15,16,21,22,24,26,28-35,37,39-53,55,58,59,61-66,67 tested prescribed herbal
decoction, and 7 (12.07%) studies20,22,24,31,34,41,65 tested Chinese herbal medicine injection.
The top ten CHMs used were Maxing Shigan Tang [麻杏石甘汤 , 15.52% (9/58)], Lianhua
Qingwen granule/capsule [连花清瘟颗粒/胶囊, 15.52% (9/58)], Xuebijing injection [血必净注射剂,
8.62% (5/58)], Dayuanyin [达原饮 , 8.62% (5/58)], Shufeng Jiedu capsule[疏风解毒胶囊 , 8.62%
(5/58)], Qingfei Paidu Tang [清肺排毒汤 , 6.90% (4/58)], Xiaochaihu Tang [小柴胡汤 , 6.90%
(4/58)], Ganlu Xiaodu Dan [甘露消毒丹, 5.17% (3/58)], Liujunzi Tang [六君子汤, 5.17% (3/58)]
and Toujie Quwen granule [透解袪瘟颗粒 , 5.17% (3/58)]. Of which, the most frequently used
Chinese patent medicine, Chinese herbal medicine injection and prescribed herbal decoction were
Lianhua Qingwen granule/capsule [连花清瘟颗粒/胶囊], Xuebijing injection [血必净注射剂], and
Maxing Shigan Tang [麻杏石甘汤], respectively.
Table 2 lists the CHM used at least twice.
Insert Table 2
3.5 Effectiveness and safety of CHM in the treatment or adjuvant treatment of COVID-19
3.5.1 Analysis for studies with control group
3.5.1.1 Primary outcomes
3.5.1.1.1 Cure rate
Five studies including one RCT14 and 4 retrospective studies with control group21-24 reported this
outcome. All 5 studies adopted the judgment criteria of the GDT of COVID-19 for cure: (1) the body
temperature returned to normal for longer than three days; (2) the respiratory symptoms improved
significantly; (3) the pulmonary imaging showed that the inflammation has obviously disappeared; (4)
the respiratory pathogenic nucleic acid, (the sampling time interval of 2 tests was at least 1day or 24
hours), and the results were both negative.
All 5 studies compared CHM plus conventional western therapy with conventional western
therapy. After analyzing separately according to the study design, the results regardless of RCTs or
retrospective studies with control group showed that there was no statistical difference between the
experimental and control groups (RR 1.42, 95% CI 0.76 to 2.62, 1 RCT; RR 1.20, 95% CI 0.98 to
1.48, 4 retrospective studies with control group).
Insert Fig.4
3.5.1.1.2 Aggravation rate
A total of 13 studies10-13,16,18,21,24,26,27,58,60,67 that compared CHM plus conventional western therapy
with conventional western therapy reported on this outcome. Of these, 2 retrospective studies with a
control group26,27 reported that there were no patients who experienced aggravation in either the
experimental or control group. After analyzing separately according to the study design of the
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remaining 11 studies, the results of RCTs or retrospective studies with control group both showed
that CHM plus conventional western therapy was better than conventional western therapy alone in
reducing aggravation rate (RR 0.46, 95% CI 0.30 to 0.68, 7 RCTs10-13,16,58,67; RR 0.37, 95% CI 0.22 to




Five studies10,16,22,24,67 that compared CHM plus conventional western therapy with conventional
western therapy reported this outcome. After analyzing separately according to the study design, the
results regardless of RCTs or retrospective studies with control group showed that there was no
statistical difference between the experimental and control groups (RR 0.45, 95% CI 0.09 to 2.13, 3
RCTs10,16.67; RR 0.66, 95% CI 0.35 to 1.27, 2 retrospective studies with control group22,24).
Insert Fig.6
3.5.1.2 Secondary outcomes
The results on secondary outcomes are shown in Table 3.
Insert Table 3
3.5.1.2.1 The disappearance rate and the duration of main symptoms (fever, cough and fatigue)
a. The disappearance rate of main symptoms
A total of 6 studies11,12,15,18,25,60 including 3 RCTs11,12,15 and 3 retrospective studies with control
group18,25,60 reported the disappearance rate of main symptoms. All studies compared CHM plus
conventional western therapy with conventional western therapy. Of these, the number of studies that
reported the disappearance rate of fever, cough and fatigue was 611,12,15,18,25,60, 611,12,15,18,25,60 and
511,12,18,25,60, respectively.
Studies which explored the resolution rate for fever, after analyzing separately according to the
study design, although the pooled data of retrospective studies with control group showed that CHM
plus conventional western therapy was better than conventional western therapy alone (RR 1.34, 95%
CI 1.13 to 1.58, 3 retrospective studies with control group), the pooled result of RCTs showed that
there was no statistical difference between the experimental and control groups (RR 1.18, 95% CI
0.88 to 1.60, 3 RCTs, I2 = 69%).
Regarding studies which investigated the disappearance rate of cough, the results of RCTs or
retrospective studies with control group both showed that CHM in combination with conventional
western therapy was superior to conventional western therapy alone (RR 1.37, 95% CI 1.15 to 1.64, 3
RCTs; RR 1.82, 95% CI 1.22 to 2.71, 3 retrospective studies with control group).
Studies reporting the disappearance rate of fatigue following COVID-19, the results regardless of
RCTs or retrospective studies with control group showed that CHM plus conventional western
therapy had a higher disappearance rate than conventional western therapy alone (RR 1.37, 95% CI
1.02 to 1.83, 2 RCTs; RR 1.48, 95% CI 1.14 to 1.93, 3 retrospective studies with control group).
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b. The duration (time to resolution) of main symptoms
A total of 10 studies17,18,21,23-25,58-60,67 including 3 RCTs58,59,67, 1 non-RCT17 and 6 retrospective
studies with control group18,21,23-25,60 reported the duration of main symptoms and all of them
compared CHM plus conventional western therapy with conventional western therapy. Of these, the
number of studies that reported the duration of fever, cough and fatigue was 1017,18,21,23-25,58-60,67,
717,18,21,23,58-60 and 617,18,23,58-60, respectively.
For the duration of fever, one study67 reported that, the CHM group exhibited a significant
improvement in time to fever resolution (P = 0.035) compared with the control group. After
analyzing separately in light of the other 9 studies’ design17,18,21,23-25,58-60, the results regardless of
RCTs, non-RCT or retrospective studies with control group showed that CHM plus conventional
western therapy was better than conventional western therapy alone (MD -2.08 days, 95% CI -2.90 to
-1.26, 2 RCTs, I2 = 60%; MD -0.83 days, 95% CI -1.22 to -0.44, 1 RCT; MD -1.54 days, 95% CI -
1.82 to -1.26, 6 retrospective studies with control group).
In shortening the duration of cough, the results regardless of RCTs or retrospective studies with
control group showed that CHM plus conventional western therapy was superior to conventional
western therapy alone (MD -2.34 days, 95% CI -3.32 to -1.37, 2 RCTs, I2 = 56%; MD -1.68 days,
95% CI -1.92 to -1.43, 4 retrospective studies with control group). However, the results from one
non-RCT showed that there was no statistical difference between the experimental and control groups
(MD 0.28 days, 95% CI -0.40 to 0.96, 1 non-RCT).
Regarding those studies reporting the duration of fatigue as secondary outcome, both RCTs and
retrospective studies with control group showed better effect for the CHM plus conventional western
therapy when compared with conventional western therapy alone (MD -2.35 days, 95% CI -2.91 to -
1.79, 1 RCT; MD -1.75 days, 95% CI -2.01 to -1.49, 3 retrospective studies with control group).
However, the result from one non-RCT showed that there was no statistical difference between the
two groups (MD -0.33 days, 95% CI -0.78 to 0.12, 1 non-RCT).
3.5.1.2.2 Negative conversion rate of nucleic acid test for SARS-Cov-19
A total of 3 retrospective studies with control group20,23,27 reported this outcome and all compared
CHM plus conventional western therapy with conventional western therapy. Pooled data from 3
studies showed that CHM in combination with conventional western therapy was superior to
conventional western therapy alone (RR 1.32, 95% CI 1.05 to 1.66) in improving the negative
conversion rate of nucleic acid test for SARS-Cov-19.
3.5.1.2.3 Inflammatory disappearance on chest CT
A total of 16 studies10,12,13,15,17-22,24,26,27,58-60 reported this outcome and all compared CHM plus
conventional western therapy with conventional western therapy.
Of these, 14 studies10,12,13,15,17,18,20,22,24,26,27,58-60 reported the number of patients with inflammatory
disappearance on chest CT (assessed as effective, effective rate = the number of patients with
inflammatory disappearance on chest CT / the total number of patients in experimental or control
group × 100%). After analyzing separately according to the study design, the results regardless of
RCTs or non-RCT showed that CHM plus conventional western therapy was better than conventional
western therapy alone (RR1.28, 95% CI 1.10 to 1.49, 6 RCTs; RR 1.21, 95% CI 1.05 to 1.40, 1 non-
RCT). However, the pooled results from 7 retrospective studies with control group showed that there
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was no statistical difference between the experimental and control groups (RR 1.23, 95% CI 1.00 to
1.52, 7 retrospective studies with control group, I2 = 67%).
The other 2 retrospective studies with control group19,21 reported the time from receiving treatment
to the beginning of inflammation disappearance and the pooled analysis from the 2 studies showed
that CHM plus conventional western therapy was superior to conventional western therapy alone in
shortening the time (MD -2.23 days, 95% CI -2.46 to -2.00, 2 retrospective studies with control
group).
3.5.1.2.4 Length of hospitalization
A total of 4 retrospective studies with control group22,24,26,58 reported length of time in hospital as
an outcome. All 4 studies compared CHM plus conventional western therapy with conventional
western therapy. The pooled analysis from the 4 studies showed that there was no statistical
difference between the experimental and control groups (MD -0.42 days, 95% CI -3.49 to 2.64, I2 =
95%) in shortening the length of hospitalization.
3.5.1.2.5 Adverse events
A total of 16 studies10,11,13-15,17,19-24,27,59,60,67 reported this outcome and all compared CHM plus
conventional western therapy with conventional western therapy. Of these, 8 studies10,13,14,19,24,27,59,60
reported that no adverse events occurred in either the experimental or control group. Pooled data
from the other 8 studies11,15,17,20-23,67 showed that there was no statistical difference between the
experimental and control groups (RR 2.06, 95% CI 0.34 to 12.38, 3 RCTs11,15,67; RR 1.00, 95% CI
0.21 to 4.84, 1 non-RCT17; RR 0.87, 95% CI 0.26 to 2.93, 4 retrospective studies with control
group20-23). The adverse events reported in these 8 studies were mild abdominal pain, diarrhea,
nausea, vomiting and drug allergy, etc.
3.5.1.3 Subgroup analysis
As all controlled studies compared CHM plus conventional western therapy with conventional
western therapy, we failed to perform the subgroup analysis based on the use of CHM with or
without conventional western therapy. Therefore, we only conducted the subgroup analysis based on
the level of severity of COVID-19 (non-serious, serious or a mix of non-serious and serious) for
primary outcomes.
With regard to cure rate, although a pooled data of 5 studies that reported this outcome showed
that CHM plus conventional western therapy was superior to conventional western therapy in
improving it (RR 1.21, 95% CI [1.01, 1.45]), the results of the subgroup analysis based on the level
of severity of COVID-19 showed that there was no statistical difference between the experimental
and control groups (RR 1.69, 95% CI 0.72 to 3.92, 2 studies14,23 involving 143 non-serious patients;
RR 1.17, 95% CI 0.91 to 1.50, 1 study22 involving 103 serious patients; RR 1.23, 95% CI 0.87 to
1.72, 2 studies21,24 involving 112 patients, a mix of non-serious and serious, I2 = 62%).
Regarding aggravation rate, a total of 11 studies10-13,16,18,21,24,58,60,67 that reported this outcome were
used to conduct meta-analysis, and the results from the 11 studies showed that CHM plus
conventional western therapy was better than conventional western therapy alone in reducing
aggravation rate (RR 0.42, 95% CI 0.31 to 0.59). Of which, 8 studies10-13,18,58,60,67 included only
patients with non-serious COVID-19, and pooled data from the 8 studies showed that CHM plus
conventional western therapy was better than conventional western therapy (RR 0.42, 95% CI 0.29 to
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0.61, 8 studies). One study16 included only patients with serious COVID-19, the results showed that
there was no statistical difference between the experimental and control groups (RR 1.00, 95% CI
0.10 to 10.11, 1 study). The remaining 2 studies21,24 included both non-serious patients and serious
patients with COVID-19, and the results from the 2 studies showed a lower aggravation rate in the
experimental group compared with the control group (RR 0.36, 95% CI 0.14 to 0.93, 2 studies).
For mortality rate, a total of 5 studies10,16,22,24,67 were included, and pooled data from 5 studies
showed that there was no statistical difference between the experimental and control groups (RR 0.62,
95% CI [0.34, 1.14]) in reducing mortality rate. The results of the subgroup analysis based on the
level of severity of COVID-19 showed that there was also no statistical difference between the two
groups (RR 0.43, 95% CI 0.06 to 2.86, 2 study10,67 involving 342 non-serious patients; RR 0.69, 95%
CI 0.36 to 1.31, 2 studies16,22 involving 145 serious patients; RR 0.18, 95% CI 0.01 to 4.23, 1 study24
involving 52 patients, a mix of non-serious and serious).
3.5.2 Analysis of case series and case reports
A total of 12 case series28-37,61,62] and 24 case reports38-57,63-66 were included in our review. Of
which, one case series29 and 7 case reports40,42,51,56,57,63,64 involving 111 patients only used CHM, and
11 case series28,30-37,61,62 and 19 case reports38,39,41,43-50,52-56,65,66 involving 828 patients used CHM plus
conventional western therapy. The authors of the 36 articles concluded that CHM with or without
conventional western therapy was beneficial for the treatment of COVID-19.
With regard to 111 patients who received CHM treatment for a period of time from 4 to 11 days,
one case series and one case report involving 100 patients reported that 42 patients were cured
(42/100), 7 case reports involving 13 patients reported that 13 patients were negative for nucleic acid
test (13/13), one case series and 6 case reports involving 54 patients reported that 30 patients with the
disappearance of fever (30/54), one case series and one case report involving 71 patients reported that
17 patients with the disappearance of cough (17/71), one case series involving 75 patients reported
that 20 patients with the disappearance of fatigue (20/75), one case series and 5 case reports
involving 96 patients reported that 87 patients (87/96) showed improvement of inflammatory
disappearance on chest CT.
For 828 patients who received CHM plus conventional western therapy for a period of time from 6
to 15 days, 4 case series and 6 case reports involving 641 patients reported that 561 patients were
cured (561/641), 6 case series and 16 case reports involving 182 patients reported that 179 patients
were negative for nucleic acid test (179/182), 5 case series and 13 case reports involving 271 patients
reported that 258 patients with the disappearance of fever (258/271), 5 case series and 3 case reports
involving 437 patients reported that 284 patients with the disappearance of cough (284/437), 5 case
series and 2 case reports involving 327 patients reported that 212 patients with the disappearance of
fatigue (212/327), and 3 case series and 11 case reports involving 525 patients reported that 483
patients (483/525) showed improvement of inflammatory disappearance on chest CT. In addition,
there were 3 case series which reported adverse events. Of these, 2 case series reported that no
adverse events occurred, and the remaining reported that 7 patients with the treatment of CHM plus
conventional western therapy experienced adverse events including vomiting (4), dizziness (2) and
rash (1).
4 Discussion
Although RCT is the gold standard to evaluate the effectiveness of interventions, but it cannot
answer all important questions about a given intervention.68 Considering the characteristics of sudden
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acute infectious diseases and the practical problems of ethics and informed consent, the
implementation of RCT faces more challenges under conventional medical conditions.69 Many
questions in medical research are investigated in observational studies having a role in research into
the benefits and harms of medical interventions68,70, having an important reference for the
preliminary evaluation of the effectiveness of CHM and clinical decision-making. In this case, other
types of studies (eg. non-RCT, retrospective studies, case-series) were included in our review.
4.1 Summary of the main findings
A total of 58 clinical studies whose purpose were to evaluate the effectiveness of CHM used with
or without conventional western therapy on COVID-19 were included. The included studies involved
RCTs, non-RCT, retrospective studies with control group, case-series and case-reports. In total the
studies involved 2773 COVID-19 patients, 1921 (69.28%) of them received CHM. The severity of
COVID-19 varied from non-serious (mild and common) and serious (severe and critical). Most of the
studies used a combination of CHM and conventional western therapy. Analysis of the frequency of
different CHM indicated that the most frequently used Chinese patent medicine, Chinese herbal
medicine injection and prescribed herbal decoction were Lianhua Qingwen granule/capsule,
Xuebijing injection, and Maxing Shigan Tang, respectively.
This review suggested that CHM in combination with conventional western therapy appeared
better than conventional western therapy alone in reducing aggravation rate, increasing the
disappearance rate or shortening the duration of main symptoms (fever, cough and fatigue),
improving the negative conversion rate of nucleic acid test, and increasing the number of patients
with inflammatory disappearance according to chest CT or alternative demonstrated a reduction in
the time needed from receiving treatment to beginning of inflammation disappearance. For the
primary outcomes, subgroup analyses were conducted based on the level of severity of COVID-19
and suggested that CHM in combination with conventional western therapy had more significant
effect than conventional western therapy in reducing aggravation rate for non-serious patients.
In terms of reducing mortality rate and shortening the length of hospitalization, there was no
statistical difference between the CHM combined conventional western therapy group and the
conventional western therapy group. Although some studies have reported adverse events (eg. mild
abdominal pain, diarrhea, nausea and vomiting) in the CHM plus conventional western therapy group,
but there was also no statistical difference between the experimental and control groups. This
suggests that the use of CHM did not increase the risk of adverse events.
Although in this review there were no pooled results for CHM used alone from controlled studies
for COVID-19, one case-series and seven case-reports that were included reported that CHM alone
may play a positive therapeutic role in the treatment of COVID-19.
4.2 Strengths and limitations
This review systematically collected the evidence from clinical studies whose purpose was to
evaluate the effect and safety of CHM with or without conventional western therapy on COVID-19.
Relevant clinical studies were analyzed from the aspects of general characteristics, quality
assessment, analysis of the use of CHM and comprehensive effect and safety evaluation of CHM for
COVID-19 patients, providing important evidence for future related research.
However, this review did not summarize the specific administration methods of CHM in all
included studies, especially considering the complexity of prescribed herbal decoction use, which
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may require further specific research in the future. Therefore, this review cannot be directly used to
guide clinical practice. In addition, all included studies were conducted in China, whether this
evidence is equally applicable to other countries outside China needs further international study.
4.3 Implications for further research
The benefits for the use of CHM for COVID-19 needs to be verified by more rigorous designed
and implemented clinical trials, especially randomized controlled trials. The following points should
be noted when conducting relevant RCTs: (1) Clear reporting of random allocation and random
concealment; (2) Application of blinding to participants, personnel (doctors), outcome evaluators
and statistical analysts; (3) Design and register the study protocol; (4) Definition of important
outcomes, such as time to cure, aggravation and mortality; (5) Selection of CHM: considering the
difficulty in the use of herbal decoction (eg, dosage of herbal medicien, especially about its use
outside China), we suggest that trials of Chinese patent medicine or herbal injection should be given
priority to verify the effects and safety of these two, so as to find safe, effective and convenient
medications to cure more COVID-19 patients as soon as possible. Unfortunately, in our this research,
we did not to perform subgroup analysis on Chinese patent medicine, herbal injection and prescribed
herbal decoction. But next, we will give priority to the relevant evidence review of existing clinical
studies on the treatment of COVID-19 with Chinese patent medicine.
5 Conclusion
Current low certainty evidence suggests that there maybe a tendency that CHM plus conventional
western therapy is superior to conventional western therapy alone. The use of CHM did not increase
the risk of adverse events.
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Search strategy Time limit
CNKI Since CNKI has set up a thematic platform for COVID - 19, the "treatment" section of the
platform was selected for manual retrieval.
As of April
30, 2020
VIP #1: M = Xinxing Guangzhuang Bingdu Bing(新型冠状病毒病) OR Xinguan Feiyan (新冠肺
炎) OR 2019 Guanzhuang Bingdu (2019冠状病毒病) OR COVID-19 OR 2019-nCOV OR
NCP
#2: M = Zhongyi (中医) OR Zhongyao (中药) OR Caoyao (草药) OR Tangji (汤剂) OR
Zhongchengyao (中成药) OR Zhusheji (注射剂) OR Zhongxiyi Jiehe (中西医结合)
#3: #1 AND #2
From January
1 to April 30,
2020
Wanfang #1: Major Topic: "Xinxing Guangzhuang Bingdu Bing (新型冠状病毒病 )" + "Xinguan
Feiyan (新冠肺炎)" + " 2019 Guanzhuang Bingdu Bing (2019冠状病毒病)" + "COVID-19"
+ "2019-nCOV" + "NCP"
#2: Major Topic: "Zhongyi (中医)" + "Zhongyao (中药)" + "Caoyao (草药)" + "Tangji (汤
剂)" + "Zhongchengyao (中成药)" + "Zhusheji (注射剂)" + "Zhongxiyi Jiehe (中西医结合)"
#3: #1 AND #2
From January
1 to April 30,
2020
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SinoMed #1: ("Xinxing Guangzhuang Bingdu Bing (新型冠状病毒病 )"[标题 :智能 ] OR "Xinguan
Feiyan (新冠肺炎 )"[标题 :智能 ] OR "2019 Guanzhuang Bingdu Bing (2019 冠状病毒
病)"[标题:智能] OR "COVID-19"[标题:智能] OR "2019-nCOV"[标题:智能] OR "NCP"[标
题:智能])
#2: ("Zhongyi (中医)"[标题:智能] OR "Zhongyao (中药)"[标题 :智能] OR "Caoyao (草
药)"[标题:智能] OR "Tangji (汤剂)"[标题:智能] OR "Zhongchengyao (中成药)"[标题:智
能] OR "Zhusheji (注射剂)"[标题:智能] OR "Zhongxiyi Jiehe (中西医结合)"[标题:智能])
#3: #1 AND #2
From January
1 to April 30,
2020
PubMed (((corona virus disease-19 OR COVID-19 OR 2019 novel coronavirus OR 2019-nCOV OR
NCP[MeSH Major Topic])) AND (Chinese medicine OR traditional Chinese medicine OR
herbal medicine OR decoction OR patent medicine OR injection OR integrated Chinese and
western medicine[MeSH Major Topic])) AND ("2020/01/01"[Date - Publication] :
"2020/04/30"[Date - Publication])
From January
1 to April 30,
2020
Emabse #1: ab,ti: corona virus disease-19 OR COVID-19 OR 2019 novel coronavirus OR 2019-
nCOV OR NCP
#2: ab,ti: Chinese medicine OR traditional Chinese medicine OR herbal medicine OR
decoction OR patent medicine OR injection OR integrated Chinese and western medicine
#3: #1 AND #2
From January
1 to April 30,
2020
ChiCTR Title search was carried out using Xinxing Guangzhuang Bingdu (新型冠状病毒 ) and










Title or abstract search was carried out using COVID-19 as search terms. As of April
30, 2020
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Figure legends
Fig.1 Flow diagram for searching and screening of published articles
Fig.2 Flow diagram for searching and screening of registered clinical studies
Fig.3 Risk of bias graph of included 10 RCTs
Fig.4 Forest plot of cure rate: CHM plus conventional western therapy versus conventional western
therapy
Fig.5 Forest plot of aggravation rate: CHM plus conventional western therapy versus conventional
western therapy
Fig.6 Forest plot of mortality rate: CHM plus conventional western therapy versus conventional western
therapy
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Age (year) The severity (*) ofCOVID-19



















Study type 1: randomized controlled trials (9, 15.79%)
Yu P10 T:82/65C:89/59
T:48.27±9.56
C:47.25±8.67 Non-serious Chinese patent medicine Yes 7 days ②③⑬ Positive
Duan C11 T:39/43C:23/18
T:51.99±13.88












C:43.68±6.45 Non-serious Chinese patent medicine Yes 10 days ②⑪⑬ Positive
Fu XXb14 T:19/18C:19/17
T:45.26±7.25




T: 46 (non-serious) / 5
(serious)
C: 11 (non-serious) / 4
(serious)
Prescribed herbal

































Study type 2: Non-randomized controlled trial (1, 1.75%)
Xiao Q17 T:64/36C:66/34
T:60.90±8.70




Study type 3: Retrospective studies with control group (11, 19.30%)
Cheng DZa18 T:26/25C:27/24
T:55.5±12.3








T: 37 (non-serious) / 7
(serious)
C: 28 (non-serious) / 8
(serious)








































T: 27 (non-serious) / 7
(serious)























T: 41 (non-serious) / 8
(serious)





Yes Notreported ②⑪⑫ Positive
Yang MB27 T:16/10C:9/14
T:50.35±13.37












Study type 4: case-series (12, 21.05%)
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Zhang Y28 9/15 49.96±12.79(27-69) Non-serious
Prescribed herbal
decoction Yes 6-14 days NA Positive
Wang RQ29 52/46 42.70±16.86 87 (non-serious) / 11(serious)
Prescribed herbal
decoction No 9 days NA Positive
Xie YF30 8 35-79 Serious Prescribed herbaldecoction Yes
Not
reported NA Positive






Yes Notreported NA Positive





Liu MJ33 36 NR Not reported Prescribed herbaldecoction Yes 14 days NA Positive






Yes Notreported NA Positive






(25-95) Non-serious Chinese patent medicine Yes
8. 0 ± 4.
10 days NA Positive
Zhou YJ37 17/23 19-68 Non-serious Prescribed herbaldecoction Yes 14 days NA Positive
Qu YF61 23/17 61.2±16.5(24-79) Non-serious
Prescribed herbal
decoction Yes 7 days NA Positive
Shi TF62 15/25 43.9±16.3(20-94)






Study type 5: case-reports (24, 42.11%)
Fu XX38 1/1 32, 46 Non-serious Chinese patent medicine Yes 10/14 days NA Positive




Yes 9 days NA Positive
Dong L40 1M 56 Not reported Prescribed herbaldecoction No 11 day NA Positive





Yes 7/18 days NA Positive
Li GW42 1/1 35, 36 1 (non-serious) / 1 (serious) Prescribed herbaldecoction No 4/6 days NA Positive
Zhao DK43 1F 41 Not reported Prescribed herbaldecoction Yes 9 days NA Positive
He Q44 2M 25, 29 Serious Prescribed herbaldecoction Yes 8/6 days NA Positive
Yang HM45 1F 74 Serious Prescribed herbaldecoction Yes 15 days NA Positive
Wang YC46 2M 33, 54 1 (non-serious) / 1 (serious) Prescribed herbaldecoction Yes
Not
reported NA Positive
Li WN47 1F 71 Serious Prescribed herbaldecoction Yes
Not
reported NA Positive
Feng QM48 1F 51 Serious Prescribed herbaldecoction Yes 15 days NA Positive
Xu JC49 1M 35 Non-serious Prescribed herbaldecoction Yes 12 days NA Positive
Liu Y50 1F 38 Non-serious Prescribed herbaldecoction Yes 7 days NA Positive




No 9 days NA Positive
Lin JZ52 1F 35 Not reported Prescribed herbaldecoction Yes 12 days NA Positive








63 2 (non-serious) / 2 (serious) Chinese patent medicine Yes
Not
reported NA Positive
Deng Z55 1F 39 Serious Prescribed herbaldecoction Yes
Not
reported NA Positive
L Ni56 1/2 27, 51, 53 Serious Chinese patent medicine 1 Yes / 2No
Not
reported NA Positive
Gao XS57 1F 42 Non-serious Chinese patent medicine No 7 days NA Positive
Li DF63 1/1 68, 47 Non-serious Prescribed herbaldecoction No
Not
reported NA Positive
Lai YG64 1/2 56, 61, 60 1 (non-serious) / 2 (not Prescribed herbal No 6/7 days NA Positive
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reported) decoction




Yes 12/14days NA Positive
Wang H66 1/1 63, 49 Non-serious Prescribed herbaldecoction Yes 10/14 days NA Positive
Note:M, male; F, female; T, treatment group involving Chinese herbal medicine; C, controlled group not involving Chinese herbal medicine; Yes, the intervention involved
in this study was Chinese herbal medicine combined with conventional western therapy; No, the intervention involved in this trial was Chinese herbal medicines alone, not
combined with conventional western therapy; NA, not applicable; Positive, Chinese herbal medicine has benefits on the treatment or adjuvant treatment of COVID-19;
negative, Chinese herbal medicine has no benefits on the treatment or adjuvant treatment of COVID-19, or can even make the disease worse.
The severity (*) was classified according to the guidelines for the diagnosis and treatment of COVID-19 released by the National Health Commission of the People’s Republic
of China. We divide them into two categories of non-serious (including mild and common) and serious (including severe and critical). ¶ All participants in this trial were
screened from patients of suspected COVID-19. Although the article did not state the COVID-19 severity of the participants included in the trial, we speculated that the
COVID-19 severity of these participants should be non-serious (in light of the clinical knowledge of COVID-19).
Outcomes:① cure rate; ② aggravation rate; ③ mortality rate; ④ the disappearance rate of fever; ⑤ the disappearance rate of cough; ⑥ the disappearance rate of fatigue;⑦
the duration of fever;⑧ the duration of cough; ⑨ the duration of fatigue; ⑩ negative conversion rate of nucleic acid test; ⑪ inflammatory disappearance on chest CT; ⑫
Length of hospitalization; ⑬ adverse events.
Table 2 Chinese herbal medicine used twice or more frequently
The name of Chinese herbal medicine (CHM) Frequency (N) Percentage
Type 1 of CHM: prescribed herbal decoction
Maxing Shigan Tang [麻杏石甘汤] 9 15.52%
Dayuanyin [达原饮] 5 8.62%
Qingfei Paidu Tang [清肺排毒汤] 4 6.90%
Xiaochaihu Tang [小柴胡汤] 4 6.90%
Ganlu Xiaodu Dan [甘露消毒丹] 3 5.17%
Liujunzi Tang [六君子汤] 3 5.17%
Sanren Tang [三仁汤] 2 3.45%
Feiyan No.1 Fang [肺炎 1号方] 2 3.45%
Xiaoqinglong Tang [小青龙汤] 2 3.45%
Wulingsan [五苓散] 2 3.45%
Type 2 of CHM: Chinese patent medicine
Lianhua Qingwen granule/capsule [连花清瘟颗粒/胶囊] 9 15.52%
Shufeng Jiedu gapsule[疏风解毒胶囊] 5 8.62%
Toujie Quwen granule [透解袪瘟颗粒] 3 5.17%
Jinhua Qinggan granule [金花清感颗粒] 2 3.45%
Shuanghuanglian oral liquid [双黄连口服液] 2 3.45%
Type 2 of CHM: Chinese herbal medicine injection
Xuebijing injection [血必净注射剂] 5 8.62%
Xiyanping injection [喜炎平注射液] 2 3.45%
Tanreqing injection [痰热清注射液] 2 3.45%
Shenfu injection [参附注射液] 2 3.45%
Shengmai injection [生脉注射液] 2 3.45%
Note: Frequency refers to the number of included studies using the CHM. Such as, the frequency of Maxing
Shigan Tang is 9, which means that nine included studies used Maxing Shigan Tang.
Percentage = (N/58) * 100%
Table 3 The pooled results of secondary outcomes of CHM used with or without conventional
western therapy for COVID-19






The pooled results References
Chinese herbal medicine + conventional
western therapy versus conventional
western therapy




3 163 RR 1.34, 95% CI 1.13 to 1.58, 18, 25, 60
●The disappearance rate of cough RCT 3 264 RR 1.37, 95% CI 1.15 to 1.64, 11, 12, 15
Retrospective 3 156 RR 1.82, 95% CI 1.22 to 2.71, 18, 25, 60








3 126 RR 1.48, 95% CI 1.14 to 1.93 18, 25, 60
●The duration of fever RCT 2 95 MD -2.08 days, 95% CI -2.90 to -1.26, I2 = 60% 58, 59




6 322 MD -1.54 days, 95% CI -1.82 to -1.26 18, 21, 23-25, 60
●The duration of cough RCT 2 95 MD -2.34 days, 95% CI -3.32 to -1.37, I2 = 56% 58, 59




4 214 MD -1.68 days, 95% CI [-1.92, -1.43] 18, 21, 23, 60
●The duration of fatigue RCT 1 45 (MD -2.35 days, 95% CI -2.91 to -1.79 59




3 136 MD -1.75 days, 95% CI -2.01 to -1.49 18, 23, 60





3 163 RR 1.32, 95% CI 1.05 to 1.66 20, 23, 27
●The effective rate of inflammatory
disappearance on chest CT
RCT 6 607 RR 1.28, 95% CI 1.10 to 1.49 10, 12, 13, 15, 58, 59




7 484 RR 1.23, 95% CI 1.00 to 1.52, I2 = 67% 18, 20, 22, 24, 26, 27,
60
●The time from receiving treatment to





2 140 MD -2.23 days, 95% CI -2.46 to -2.00 19, 21
●Length of hospitalization Retrospective
study with
control group
4 290 MD -0.42 days, 95% CI -3.49 to 2.64, I2 = 95% 22, 24, 26, 60
●Adverse events RCT 3 270 RR 2.06, 95% CI 0.34 to 12.38 11, 15, 67




4 276 RR 0.87, 95% CI 0.26 to 2.93 20-23
Chinese herbal medicine versus
conventional western therapy
None
Note: RR, risk ratio; MD, mean difference; CI, confidence interval; RCT, randomized controlled trial; Non-RCT, non-randomized controlled trial.
